Brian Henick, MD
Overview
Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick’s clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These efforts entail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events from immunotherapy.
Areas of Expertise / Conditions Treated
- Esophageal Cancer
- Immunotherapy
- Lung Cancer
- Mesothelioma
- Thoracic Cancer
- Thoracic Lung Cases
- Thoracic Oncology
- Thymoma
Academic Appointments
- Assistant Professor of Medicine at CUMC
Administrative Titles
- Associate Director, Experimental Therapeutics
- Director of Translational Research, Upper Aerodigestive Cancers in Medical Oncology
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- NYP Employee Plan
- NY Signature
- Student Health
Affinity Health Plan
- Medicaid Managed Care
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- Medicare Managed Care
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- SelectHealth
- Special Needs
WellCare
- Medicare Managed Care
- New Jersey Services (Medicaid Managed Care)
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- New Jersey Medical School
- Internship: Yale New Haven Hospital
- Residency: Yale New Haven Hospital
- Fellowship: Yale New Haven Hospital
Board Certifications
- Internal Medicine
Honors & Awards
Gold Humanism Honor Society (2011)
CCF/ASCO Young Investigator Award (2017)
SITC Sparkathon (2017-18)
CCF/ASCO Merit Award (2018)
ASCO Journals Editorial Fellowship (2018)
Research
Collaborating with several laboratories at the HICCC (especially Dr. Hiroshi Nakagawa, Dr. Steven Reiner and Dr. Anil K. Rustgi), Dr. Henick is developing personalized blood- and imaging-based biomarkers to guide precision cancer therapy, and to leverage cutting-edge model systems to test and enhance novel treatment approaches. Dr. Henick has presented his work at national conferences such as ASCO, and his accolades include induction to the Gold Humanism Honor Society, research awards from the EGFR Resisters and Conquer Cancer Foundation/ASCO, and selection to the SITC Sparkathon and IASLC Academy. He was a Top Reviewer for the Journal of Clinical Oncology, Precision Oncology, where he was the inaugural Editorial Fellow and currently serves on the editorial board.
A “Minority/Underserved-NCORP Champion”, Dr. Henick is committed to enhancing representation of underserved minority groups in our clinical trials to help assure that all patients may benefit from the results of his research. He will be Columbia’s site lead for an upcoming NYC-wide effort to study the effects of immunotherapy in underserved minority patients with lung cancer.
